|
J Biol Chem, Vol. 273, Issue 28, 17832-17838, July 10, 1998
Differential Expression of Agrin in Renal Basement Membranes As
Revealed by Domain-specific Antibodies*
C. J. Ilse
Raats ,
Marinka A. H.
Bakker,
Werner
Hoch§,
Wim P. M.
Tamboer,
Alexander J. A.
Groffen¶,
Lambert P. W. J.
van den Heuvel¶,
Jo H. M.
Berden, and
Jacob
van den Born
From the Division of Nephrology, ¶ Department of Pediatrics,
University Hospital St. Radboud, 6500 HB, Nijmegen, The Netherlands
and the § Department of Biochemistry, Max Planck Institut
für Entwicklungsbiologie, 72076 Tübingen, Germany
 |
ABSTRACT |
We determined the specificity of two hamster
monoclonal antibodies and a sheep polyclonal antiserum against heparan
sulfate proteoglycan isolated from rat glomerular basement membrane.
The antibodies were characterized by enzyme-linked immunosorbent assay on various basement membrane components and immunoprecipitation with
heparan sulfate proteoglycan with or without heparitinase pre-treatment. These experiments showed that the antibodies
specifically recognize approximately 150-, 105-, and 70-kDa core
proteins of rat glomerular basement membrane heparan sulfate
proteoglycan. Recently, we showed that agrin is a major heparan sulfate
proteoglycan in the glomerular basement membrane (Groffen, A. J. A., Ruegg, M. A., Dijkman, H. B. P. M., Van
der Velden, T. J., Buskens, C. A., van den Born, J., Assmann,
K. J. M., Monnens, L. A. H., Veerkamp, J. H.,
and van den Heuvel, L. P. W. J. (1998) J. Histochem. Cytochem. 46, 19-27). Therefore, we tested whether
our antibodies recognize agrin. To this end, we evaluated staining of
Chinese hamster ovary cells transfected with constructs encoding
full-length or the C-terminal half of rat agrin by analysis on a
fluorescence-activated cell sorter. Both hamster monoclonals and the
sheep antiserum clearly stained cells transfected with the construct
encoding full-length agrin, whereas wild type cells and cells
transfected with the construct encoding the C-terminal part of agrin
were not recognized. A panel of previously characterized monoclonals, directed against C-terminal agrin, clearly stained cells transfected with either of the constructs but not wild type cells. This indicates that both hamster monoclonals and the sheep antiserum recognize epitopes on the N-terminal half of agrin. By immunohistochemistry on
rat renal tissue, we compared distribution of N-terminal agrin with
that of C-terminal agrin. The monoclonal antibodies against C-terminal
agrin stained almost exclusively the glomerular basement membrane,
whereas the anti-N-terminal agrin antibodies recognized all renal
basement membranes, including tubular basement membranes. Based on
these results, we hypothesize that full-length agrin is predominantly
expressed in the glomerular basement membrane, whereas in most other
renal basement membranes a truncated isoform of agrin is predominantly
found that misses (part of) the C terminus, which might be due to
alternative splicing and/or posttranslational processing. The possible
significance of this finding is discussed.
 |
INTRODUCTION |
Heparan sulfate proteoglycans
(HSPGs)1 are composed of a
core protein to which anionic heparan sulfate (HS) side chains are attached. Apart from its presence in basement membranes (BMs), HSPG is
found in other extracellular matrices and on many, if not all, cell
surfaces (1-3). The first extracellular matrix HSPG that was isolated
(from mouse Engelbreth-Holm-Swarm sarcoma), characterized, and cloned
was perlecan, named after its beads-on-a-string-like appearance in
rotary shadowing electron microscopy (4-6). Different isoforms of
perlecan have been found, which appear to be the result of alternative
splicing (7, 8). Agrin is another extracellular matrix HSPG that is not
related to perlecan (9, 10). Agrin was first isolated from the electric
organ of Torpedo (11) and was recently identified as an HSPG
(12). During formation of the neuromuscular junction, motor neurons
provide a number of signals that promote the differentiation of the
post-synaptic membrane. An early signal is the secretion of specific
isoforms of agrin and their incorporation into the basal lamina. Agrin initiates the clustering of nicotinic acetylcholine receptors and other
components of the muscle cell surface at the site of contact with axons
of motor neurons (13-16). The structure of the agrin molecule and the
functions of the various domains is extensively studied and presently
well understood (17). The C terminus of agrin contains several homology
regions with the G-domain of laminin and four epidermal growth
factor-like repeats (18). The binding site of agrin to -dystroglycan
is located on the C terminus as well. Agrin binds to -dystroglycan
via its laminin G repeats (19). Furthermore, a heparin/HS binding site
is located on the C terminus and binding of heparin or HS prevents
clustering of the acetylcholine receptors, indicating that HSPGs
mediate this activity (20-22). Most alternative splicing sites have
been identified in the C terminus, three on rat agrin called x, y, and
z and two on chick and Torpedo agrin called A and B,
corresponding to rat y and z. This alternative splicing affects the
activity of agrin to cluster acetylcholine receptors. The most active
forms only occur in neural tissue, whereas the isoforms from non-neural
tissue are less active (14, 23-25). This suggests that splicing is
regulated in a tissue-specific manner. The N-terminus of agrin contains nine domains homologous to the Kazal family of protease inhibitors and
several laminin III homology regions (18). On the N-terminal half of
agrin, several attachment sites for HS side chains are found. Up until
now, only one alternative splicing site has been found in the
N-terminus. The insert on the N-terminal half is required for binding
to the extracellular matrix which is mediated by laminin (26-28).
Expression of agrin is not restricted to neurons. Agrin mRNA can be
detected in a wide range of different tissues (24), and the agrin
protein has been demonstrated to be a basal lamina component in many
tissues including kidney during early development (29). Recently, we
have shown the presence of agrin in the glomerular basement membrane
(glomerular BM) in adult human kidney (30).
In this study, we raised and characterized two hamster monoclonal
antibodies (mAbs) and a sheep polyclonal antiserum against rat
glomerular BM HSPG. The specificity of the mAbs is studied on Chinese
hamster ovary (CHO) cells that are transfected with constructs coding
for full-length agrin or the C-terminal half of agrin. These studies
showed that these antibodies recognize epitopes on the N-terminal half
of agrin. The staining on rat kidney tissue of these mAbs is compared
with that of different mAbs against well-defined epitopes on the C
terminus of agrin. These experiments suggest that most renal BMs except
the glomerular BM express a truncated isoform of agrin that lacks (part
of) the C-terminal half due to alternative splicing and/or
posttranslational processing. We speculate on the possible involvement
of the C terminus of agrin in glomerular function.
 |
MATERIALS AND METHODS |
HSPG Purification
For immunization, rat glomerular HSPG was isolated from rat
glomeruli (31). Proteoglycans were isolated by guanidine extraction, dialysis against urea, DEAE ion-exchange chromatography, chondroitinase ABC digestion (Sigma) and by fast protein liquid Q-Sepharose
chromatography. For immunoprecipitation, HSPG was isolated from rat
glomerular BM obtained by a detergent procedure (32), from which
proteoglycans were isolated as described (31). All procedures were
performed at 4 °C in the presence of 10 mM sodium EDTA,
1 mM phenylmethylsulfonyl fluoride, 5 mM
benzamidine HCl, and 10 mM N-ethylmaleimide.
Antibody Production
Male Chinese hamsters were immunized with rat glomerular HSPG
according to a previously described protocol (31). Hybridomas were
screened in indirect immunofluorescence (IF) on rat kidney cryostat
sections (see below) for a staining pattern comparable with the
staining of previously described mAbs against human glomerular BM HSPG,
which primarily stain the glomerular BM in a bright linear pattern and
the tubular BMs to a lesser extent (33). Two hybridomas were found to
meet these criteria, called MI-90 and MI-91, and were subcloned twice
by limiting dilution so that all subclones displayed the same
reactivity pattern. From these two clones, ascites production was
elicited in nude mice.
A sheep was immunized intracutaneously with rat glomerular HSPG
according to a previously described protocol (32), and after the last
booster the sheep was bled and the serum (called GR-14) was collected.
Characterization of Antibodies
Enzyme-linked Immunosorbent Assay--
The reactivity of the
antibodies with various BM components was determined in ELISA as
described (34). Rat glomerular BM HSPG, human glomerular BM HSPG
(isolated as described, Ref. 32), rat L2-laminin, mouse fibronectin,
mouse collagen type IV (all from Sigma; all at 1 µg/well), and HS
from bovine kidney (Seikagaku Kogyo, Tokyo, Japan; 5 µg/well) were
coated in PBS. Primary antibodies MI-90 and MI-91 were diluted 1:100,
and GR-14 was diluted 1:1000. The following peroxidase-conjugated
secondary antibodies in a dilution of 1:500 were used: rabbit
anti-hamster IgG (Nordic, Tilburg, The Netherlands) for mAb MI-90, goat
anti-hamster IgG (Cappel-Organon Teknika, Turnhout, Belgium) for mAb
MI-91, and rabbit anti-sheep Ig (Cappel) for GR-14.
Immunoprecipitation and SDS-PAGE--
Rat glomerular BM HSPG was
labeled with 125I according to the chloramine T-method
(35). Part of the sample was treated with heparitinase (EC 4.2.2.8;
from Sigma) 1 unit/ml in 10 mM HEPES, pH 7.0, containing 2 mM CaCl2 for 6 h at 43 °C. Radiolabeled
HSPG was pre-absorbed with protein G-Sepharose CL-4B to remove eventual radiolabeled IgG. Normal hamster IgG and culture supernatants of mAbs
MI-90 and MI-91 were incubated with protein G-Sepharose, to which goat
anti-hamster IgG (Cappel) was immobilized. Normal mouse IgM (MOPC-104E;
Bionetics, Kensington, MD) and mouse anti-HS side chain mAb JM-403 (31,
36) were incubated with protein G-Sepharose to which goat anti-mouse
IgM (Cappel) was immobilized. Normal sheep IgG and sheep antiserum
GR-14 were directly coupled to protein G-Sepharose. After washing with
PBS-Tween, the immobilized antibodies were incubated overnight at
4 °C with radiolabeled rat glomerular BM HSPG (with or without
heparitinase pretreatment). After washing in PBS-Tween, sample buffer
containing 5% -mercaptoethanol was added, the sample was boiled for
3 min and centrifuged, and the supernatant was subjected to
polyacrylamide gel electrophoresis on a 7% homogenous gel. The gel was
dried and used for autoradiography for 3 days at 70 °C.
Agrin-transfected CHO Cells--
To investigate the reactivity
of our antibodies with agrin, we used CHO-cells, stably transfected
with constructs encoding full-length rat agrin or the C-terminal half
of agrin (construct N1, amino acids 1137-1940) (17). The cells were
cultured as described (17) and continuously selected for the presence
of the construct by Geneticin (G418, 500 µg/ml; Life Technologies, Inc., Paisly, Scotland). Untransfected CHO cells were used as a
negative control. On cytospins of CHO cells, indirect IF was performed
with anti-HSPG mAbs MI-90, MI-91 antiserum GR-14, and anti-agrin mAb
Agr-131 (17) (Table I) as described for
the kidney cryostat sections (see below). For analysis by
fluorescence-activated cell sorter (FACS), samples of 100 µl of cell
suspension containing 5 × 106 cells were
permeabilized and fixed with 1 ml of PermeaFix (Ortho Diagnostic,
Beerse, The Netherlands) according to the instructions of the
manufacturer. The cells were incubated with 100 µl of primary antibody (Table I) for 30 min at 0 °C. The cells were washed and
incubated with fluorescein isothiocyanate-conjugated secondary antibody
for 30 min at 0 °C. The cells were washed twice and kept in 1%
paraformaldehyde until analysis on a Coulter Epics XL flow cytometer
(Coulter Corp., Hialeah, FL). Mean fluorescence was determined on a
scale between 0 and 1024, and values were corrected for staining by the
secondary antibody alone.
Indirect Immunofluorescence
Indirect IF was performed as described previously (34) on 2 µm
cryostat sections of rat kidney. To evaluate the specificity of the
hamster and sheep antibodies for the HSPG core protein, pretreatment of
rat kidney cryostat sections was performed by incubating nonfixed
sections with 0.25 units/ml heparitinase in 10 mM HEPES, pH
7.0, containing 2 mM CaCl2 for 30 min at
37 °C.
 |
RESULTS |
Antibody Reactivity with Basement Membrane Components in
ELISA--
The reactivity of hamster mAbs MI-90 and MI-91 and sheep
antiserum GR-14 in ELISA with different BM components is shown in Fig.
1. For MI-90, a clear reactivity was
observed with both rat glomerular BM HSPG and human glomerular BM HSPG.
For MI-91, a reactivity was observed with rat glomerular BM HSPG, but
not with human glomerular BM HSPG. Neither of the mAbs bound to rat
L2-laminin, mouse fibronectin, mouse collagen IV, or HS. Antiserum
GR-14 bound to rat glomerular BM HSPG, human glomerular BM HSPG, and to
a lesser extent to rat L2-laminin, but not to the other BM
components.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 1.
Reactivity of MI-90, MI-91, and GR-14 with BM
components in ELISA. Rat glomerular BM HSPG, human glomerular BM
HSPG, rat L2-laminin, mouse fibronectin, mouse collagen type IV, or HS
were coated. Primary antibodies MI-90 and MI-91 were diluted 1:100, and
GR-14 was diluted 1:1000. Results are expressed as absorption units at
450 nm.
|
|
Immunoprecipitation and SDS-PAGE--
After immunoprecipitation of
intact, 125I-labeled rat glomerular BM HSPG with hamster
mAbs MI-90, MI-91, and sheep antiserum GR-14, gel electrophoresis and
autoradiography revealed a broad smear with a molecular mass larger
than 220 kDa, which might have resulted from different core proteins
and/or different extent of glycosylation (Fig.
2, lanes 2, 3, and
7). This is in agreement with previous findings (32). The
same band is seen with the mouse anti-HS side chain mAb JM-403
(lane 5) (33). To assess the molecular mass of the HSPG core
protein(s), HSPG was treated before immunoprecipitation with
heparitinase to degrade the HS glycosaminoglycan side chains. This
resulted in a major band of ~170 kDa and several bands with molecular
masses of ~105 and 70 kDa, which were equal for MI-90, MI-91, and
GR-14 (lanes 9, 10, and 14). mAb JM-403 directed
against HS side chain, however, is negative after treatment with
heparitinase, as expected (lane 12). Non-relevant
hamster IgG (lanes 1 and 8), mouse IgM
(lanes 4 and 11), and normal sheep IgG
(lanes 6 and 13) with the same Ig concentration
served as negative controls. These results indicate that the mAbs MI-90
and MI-91 and the sheep antiserum GR-14 are directed against the core
protein(s) of an HSPG present in rat glomerular BM.

View larger version (106K):
[in this window]
[in a new window]
|
Fig. 2.
Immunoprecipitation of rat glomerular BM HSPG
by MI-90, MI-91, and GR-14. 125I-labeled rat
glomerular BM HSPG, without (lanes 1-7) or with
pre-treatment of heparitinase (HS ase) (lanes
8-14), was immunoprecipitated by immobilized hamster IgG
(lanes 1 and 8), hamster mAb MI-90 (lane
2 and 9), hamster mAb MI-91 (lanes 3 and
10), mouse IgM (lanes 4 and 11), mouse
mAb JM-403 (lanes 5 and 12), sheep IgG
(lanes 6 and 13), or sheep antiserum GR-14
(lanes 7 and 14), separated by SDS-PAGE, and
visualized by autoradiography.
|
|
Indirect Immunofluorescence on CHO Cells Transfected with Agrin
Constructs--
To evaluate recognition of rat agrin by our
antibodies, indirect IF was performed on CHO cells transfected with
constructs encoding full-length agrin (37) or the C-terminal half of
agrin (N1) (25). Binding of antibodies was evaluated either
microscopically on cytospins or by FACS analysis. First, microscopical
evaluation of cytospins showed that both hamster anti-HSPG mAbs MI-90
and MI-91 and sheep anti-HSPG GR-14 recognized full-length agrin as expressed by CHO cells transfected with full-length agrin (Fig. 3, A-C), whereas they did not
bind to the C-terminal half of agrin as expressed by cells transfected
with construct N1 (Fig. 3, E-G, Table
II). Neither did they bind to wild type
CHO cells. The positive control anti-agrin mAb Agr-131 bound to both
full-length agrin and to the C-terminal half of agrin as expressed by
cells transfected with full-length agrin or construct N1, respectively
(Fig. 3, D and H, Table II) To confirm this
crucial conclusion, we also performed fluorescence analysis by FACS and
quantified mean fluorescence intensity. As shown in Table II,
full-length agrin expressed by CHO cells is recognized by both hamster
mAbs and the sheep antiserum. These antibodies, however, were negative
on N1-transfected cells and on wild type CHO cells. Anti-agrin mAb
Agr-131, however, recognized both full-length and C-terminal agrin.
These results indicate that hamster mAbs MI-90 and MI-91 and the sheep
antiserum GR-14 recognize epitopes on the N-terminal half of agrin.

View larger version (66K):
[in this window]
[in a new window]
|
Fig. 3.
Agrin staining of MI-90, MI-91, GR-14, or
Agr-131 on CHO cells. Cytospins of CHO cells transfected with
constructs encoding full-length agrin (A-D) or the
C-terminal half of agrin (E-H) were stained with MI-90
(A and E), MI-91 (B and F),
GR-14 (C and G), or anti-agrin Agr-131
(D and H) in indirect immunofluorescence
(magnification, × 200; exposure time, 8 s).
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Staining of agrin-expressing CHO cells by MI-90, MI-91, GR-14, and
Agr-131
Cytospins or FACS of CHO cells transfected with constructs
coding for either full-length agrin or the C-terminal half of agrin or
wild type CHO cells stained with hamster mAbs MI-90, MI-91, sheep
antiserum GR-14, or anti-agrin mAb Agr-131. Staining on cytospin
preparations is quantified as follows: , negative; +, weak; ++,
moderate; +++, strong. Staining intensity on the FACS is quantified as
mean fluorescence intensity (on a scale from 0 to 1024). Results from
one representative out of four experiments are shown.
|
|
Distribution of Agrin in Rat Kidney--
In indirect IF, mAbs
MI-90 and MI-91 stain most BMs in a linear way, the glomerular BM with
the highest intensity (Fig. 4, A and B). This staining pattern closely resembles
the staining of previously developed mAbs directed against human
glomerular BM HSPG (38). Only mAb MI-91 weakly stained Bowman's
capsule and BMs of smooth muscle cells in arteries and arterioles. Both mAbs stained BMs of endothelial cells in blood vessels but not the
mesangial matrix and peritubular capillaries. (Fig. 4, A and B) mAb MI-90 also stained human kidney cryostat sections,
and mAb MI-91 also stained mouse kidney cryostat sections. (Table III). The polyclonal antiserum GR-14
stained the glomerular BM, all tubular BMs, and BMs of endothelial
cells in a bright linear way but not the mesangial matrix nor the
peritubular capillaries. Bowman's capsule, and the smooth muscle cells
in arteries and arterioles were stained weakly (Fig. 4C).
This staining pattern is similar to that of a previously described
polyclonal antibody directed to human glomerular BM HSPG (32). GR-14
also stained human and mouse kidney cryostat sections. (Table III) The
staining pattern of MI-90, MI-91 and GR-14 could not be prevented by
pre-treatment of the sections with heparitinase, indicating that the
antibodies are directed against the core protein of HSPG. mAb JM-403
directed against the HS side chain, however, was negative after
treatment with heparitinase, as expected. This confirms our data from
the immunoprecipitation with heparitinase-pretreated glomerular BM HSPG
(Fig. 2, lanes 8-14).

View larger version (111K):
[in this window]
[in a new window]
|
Fig. 4.
Agrin staining of MI-90, MI-91, GR-14, or
Agr-131 on rat kidney. Indirect immunofluorescence with MI-90
(A), MI-91 (B), GR-14 (C), anti-agrin
Agr-131 (D) on rat kidney cryostat sections (magnification, × 200; exposure time, 8 s).
|
|
View this table:
[in this window]
[in a new window]
|
Table III
Kidney staining of agrin by MI-90, MI-91, GR-14, and Agr-131
Indirect immunofluorescence of MI-90, MI-91, GR-14, or Agr-131 on rat,
human, and mouse renal tissue. GBM, glomerular basement membrane; TBM,
tubular basement membrane; MM, mesangial matrix; BC, Bowman's capsule;
PTC, peritubular capillaries; VSM, vascular smooth muscle; ND, not
determined.
|
|
Five different mAbs directed against well-defined domains in the
C-terminal half of agrin were described earlier (17). They predominantly stain the glomerular BM, whereas most other BMs were not
stained at all. Also, Bowman's capsule is stained weakly and
segmentally (Fig. 4D, Table III). This staining is clearly different from that of our hamster mAbs which are directed against N-terminal domains of agrin and stain almost all renal BMs. These data
suggest that different isoforms of agrin are expressed in the kidney. A
large agrin isoform is found in the glomerular BM, containing both the
C-terminal part (stained by five mouse anti-C-terminal agrin mAbs) and
N terminus (stained by both hamster mAbs and the polyclonal antiserum).
On the contrary, one or more smaller isoforms are found in all other
renal BMs, which miss (part of) the C terminus (negative with all mAbs
against the C-terminal half of agrin), but contain the N terminus of
agrin (stained by our hamster mAbs and the sheep antiserum). This
conclusion could also explain our results in the immunoprecipitation
study in which several core proteins, differing with respect to their
molecular mass, were found by the hamster and sheep antibodies.
However, these differences in molecular size can also be due to
proteolysis.
 |
DISCUSSION |
In the present study, we characterized the N-terminal
agrin specificity of two hamster mAbs MI-90 and MI-91 and a
sheep polyclonal antiserum GR-14 raised against rat glomerular
BM HSPG. Furthermore, we showed a differential agrin
expression in renal BMs by comparing our antibodies with
well-defined mAbs directed against the C terminus of agrin. The
specificity of the antibodies was evaluated by means of ELISA on
various BM components and by immunoprecipitation with isolated rat
glomerular BM HSPG. In these experiments, it is shown that both hamster
mAbs and the sheep antiserum recognize the core protein(s) of an HSPG
present in rat glomerular BM with molecular masses of ~170, 105 and
70 kDa. The smaller molecules can be the result of proteolysis during
purification; however, this is less likely since the whole purification
procedure was performed at 4 °C in the presence of protease
inhibitors. These molecular weights are in agreement with previous
observations with human glomerular BM HSPG (32, 39). Both hamster mAbs
and the sheep antiserum recognize epitopes on the N-terminal half of
agrin as shown by immunofluorescence on CHO cells transfected with
various constructs coding for full-length agrin or parts of the agrin
molecule. This is in agreement with our recent observation that
anti-agrin mAbs recognized glomerular BM HSPG (30). The conclusion that
our antibodies recognize epitopes in the N-terminal half of agrin is
based on the observation that they stain full-length agrin but not the
C-terminal half of agrin. One could argue that our hamster mAbs and
sheep antiserum need tertiary epitopes, which could not be present in
the C-terminal half of agrin due to inadequate folding in the absence
of the N terminus. Other observations, however, contradict this
possibility. The mAbs directed against the C-terminal half of agrin are
able to stain both full-length and C-terminal agrin, suggesting normal
folding of the C terminus. Furthermore, the polyclonal antiserum GR-14
stains full-length agrin but not the C-terminal half of agrin,
notwithstanding the ability of most polyclonal antibodies to recognize
linear as well as tertiar epitopes. Moreover, the staining pattern of
the hamster mAbs on rat kidney cryostat sections is different from that
of the mAbs against the C-terminal half of agrin. These results
strongly suggest that the hamster mAbs and the sheep antiserum
recognize epitopes in the N-terminal half of agrin.
Polyclonal antiserum GR-14 demonstrated some cross-reactivity with rat
L2-laminin. Two possibilities can explain this observation. The
antiserum might recognize the laminin III homology regions which are
present on the N-terminal half of agrin (18) and might therefore
cross-react with laminin. Second, a low titer of anti-rat laminin
antibodies may be present in the polyclonal antiserum due to minor
contamination of the antigen with laminin. This is certainly possible,
given the laminin-binding properties of agrin (28).
On rat kidney cryostat sections, the hamster mAbs stain all renal BMs
in a bright, linear pattern but the glomerular BM with highest
intensity. This staining pattern closely resembles that of previously
developed mAbs directed against human glomerular BM HSPG (38). On the
other hand, the mAbs directed against well-defined epitopes on the C
terminus of agrin almost exclusively stain the glomerular BM. This
indicates the existence of multiple isoforms of agrin in the kidney,
namely a large agrin containing both C- and N terminus predominantly
expressed in the glomerular BM. A shorter variant missing C-terminal
regions is present predominantly in other renal BMs. One possible
explanation for the generation of this shorter form is alternative
splicing. While three alternative splicing sites have been identified
on the C-terminal half of agrin, these cannot be responsible for our
observation. Each of these sites allows the insertion of small peptide
sequences and none of them codes for a new stop codon that could result
in a truncated form of agrin (24-27). Furthermore, without the
insertions on all the alternative splicing sites known (three sites on
the C-terminal half and one on the N terminus), the molecular mass would be reduced by ~5.7 kDa. Therefore, alternative splicing alone
cannot explain the molecular masses of 170 kDa and lower that we found
for agrin. An alternative explanation for the presence of smaller
isoforms is posttranslational processing of the agrin core protein. The
predicted molecular mass of agrin is ~225 kDa (12, 18, 26). Smaller
isoforms of agrin, however, have also been found. Nitkin et
al. (40) describe agrin isoforms in the electric organ of
Torpedo with molecular masses of 150, 135, 95, and 70 kDa.
Godfrey (23) found agrin isoforms in Torpedo electric organ
of 80 and 60 kDa and in adult chicken kidney, embryonic skeletal
muscle, brain, and spinal cord of 90, 80, 72, and 60 kDa. In rat
embryonic brain, spinal cord, and muscle, agrin isoforms of 200, 175, 135, and 115 kDa have been identified (18). In adult chick kidney,
isoforms of 160 and 130 kDa are observed (41). Hagen et al.
(9) have isolated HSPG isoforms from bovine tubular BM with core
protein molecular masses of 145, 125, 88, and 83 kDa. From this HSPG,
three tryptic peptides show homology to the N terminus of rat agrin,
indicating that in tubular BM an HSPG isoform is present that is
homologous to the N terminus of agrin (9, 26). An antiserum against
this bovine tubular BM HSPG stained all renal BMs in a linear way,
identical to our hamster and sheep antibodies. These data clearly show
the existence of smaller agrin isoforms that presumably are the result
of alternative splicing and/or posttranslational modification
(possibly proteolytic processing).
Differential post-translational modification of agrin in glomeruli and
tubuli implies that either a proteinase which is able to cleave agrin
or a proteinase-inhibitor is differentially expressed in glomeruli and
tubuli. Until now, however, no comparative studies on the differential
expression of proteinases and/or proteinase-inhibitors in glomeruli and
tubuli have been performed.
What might be the function of C-terminal agrin expression exclusively
in the glomerular BM? The glomerular BM is an important part of the
filtration barrier of the glomerular capillary wall. The HS side chains
of HSPG contribute to the net negative charge of the glomerular BM,
which is thought to be responsible for the charge-selective
permeability of the glomerular filtration barrier (42, 43). These HS
side chains, however, are attached to the N-terminal half of agrin and
are consequently not specific for the glomerular BM. The C-terminal
half of agrin contains a HS/heparin binding site and the binding
regions for the receptors muscle-specific kinase (MuSK) and
-dystroglycan. The HS/heparin binding site is only present in agrin
isoforms containing the insert at the y-position in rat or A-position
in chick and Torpedo, and this alternatively spliced isoform
is only present in neuronal tissue (44, 45), excluding a role for this
HS/heparin binding site in the glomerulus. The agrin receptor MuSK is
only expressed in skeletal muscle where it is essential for the
acetylcholine receptor clustering activity of agrin. This rules out a
possible involvement of MuSK in the glomerulus (46-48). The agrin
receptor -dystroglycan was shown to play a role in epithelial
development in kidney (49). Although it has been isolated from adult
chick kidney, its presence in the glomerulus remains to be shown
(50).
In conclusion, the present study shows that in the glomerular BM
predominantly a large agrin isoform is expressed, whereas in most other
renal BMs predominantly a truncated agrin isoform is found that misses
(part of) the C-terminal region.
 |
ACKNOWLEDGEMENTS |
We thank Cor Jacobs and Sigrun Helms for
excellent technical assistance.
 |
FOOTNOTES |
*
This study was supported by grants from the Dutch Kidney
Foundation (Grants C93.1318 and C93.1309) and the Dutch Diabetes Foundation (Grant DFN 940-10-009).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Division of Nephrology
(545), University Hospital St. Radboud, P. O. Box 9101, 6500 HB
Nijmegen, The Netherlands. Tel.: 31-24-361-6539; Fax: 31-24-354-0022;
E-mail: C.Raats{at}nefro.azn.nl.
1
The abbreviations used are: HSPG, heparan
sulfate proteoglycan; HS, heparan sulfate; BM, basement membrane; CHO,
Chinese hamster ovary; mAb, monclonal antibody; PBS, phosphate-buffered
saline; IF, immunofluorescence; ELISA, enzyme-linked immunosorbent
assay; FACS fluorescence-activated cell sorter; PAGE, polyacrylamide gel electrophoresis; MuSK, muscle-specific kinase.
 |
REFERENCES |
-
Gallagher, J. T.
(1989)
Curr. Opin. Cell Biol.
1,
1201-1218[Medline]
[Order article via Infotrieve]
-
David, G.
(1993)
FASEB J.
7,
1023-1030[Abstract]
-
Lindahl, U.,
Lidholt, K.,
Spillmann, D.,
and Kjellen, L.
(1994)
Thromb. Res.
75,
1-32[CrossRef][Medline]
[Order article via Infotrieve]
-
Noonan, D. M.,
Fulle, A.,
Valente, P.,
Cai, S.,
Horigan, E.,
Sasaki, M.,
Yamada, Y.,
and Hassell, J. R.
(1991)
J. Biol. Chem.
266,
22939-22347[Abstract/Free Full Text]
-
Murdoch, A. D.,
Dodge, G. R.,
Cohen, I.,
Tuan, R. S.,
and Iozzo, R. V.
(1992)
J. Biol. Chem.
267,
8544-8557[Abstract/Free Full Text]
-
Kallunki, P.,
and Tryggvason, K.
(1992)
J. Cell Biol.
116,
559-571[Abstract/Free Full Text]
-
Joseph, S. J.,
Ford, M. D.,
Barth, C.,
Portbury, S.,
Bartlett, P. F.,
Nurcombe, V.,
and Greferath, U.
(1996)
Development
122,
3443-3452[Abstract]
-
Noonan, D. M.,
and Hassell, J. R.
(1993)
Kidney Int.
43,
53-60[Medline]
[Order article via Infotrieve]
-
Hagen, S. G.,
Michael, A. F.,
and Butkowski, R. J.
(1993)
J. Biol. Chem.
268,
7261-7269[Abstract/Free Full Text]
-
Groffen, A. J. A.,
Hop, F. W. H.,
Tryggvason, K.,
Dijkman, H. B. P. M.,
Assmann, K. J. M.,
Veerkamp, J. H.,
Monnens, L. A. H.,
and van den Heuvel, L. P. W. J.
(1997)
Eur. J. Biochem.
247,
175-182[Medline]
[Order article via Infotrieve]
-
Godfrey, E. W.,
Nitkin, R. M.,
Wallace, B. G.,
Rubin, L. L.,
and McMahan, U. J.
(1984)
J. Cell Biol.
99,
615-627[Abstract/Free Full Text]
-
Tsen, G.,
Halfter, W.,
Kroger, S.,
and Cole, G. J.
(1995)
J. Biol. Chem.
270,
3392-3399[Abstract/Free Full Text]
-
Bowe, M. A.,
and Fallon, J. R.
(1995)
Annu. Rev. Neurosci.
18,
443-462[CrossRef][Medline]
[Order article via Infotrieve]
-
Ferns, M.,
Hoch, W.,
Campanelli, J. T.,
Rupp, F.,
Hall, Z. W.,
and Scheller, R. H.
(1992)
Neuron
8,
1079-1086[CrossRef][Medline]
[Order article via Infotrieve]
-
McMahan, U. J.
(1990)
Cold Spring Harbor Symp. Quant. Biol.
55,
407-418[Abstract/Free Full Text]
-
Campanelli, J. T.,
Hoch, W.,
Rupp, F.,
Kreiner, T.,
and Scheller, R. H.
(1991)
Cell
67,
909-916[CrossRef][Medline]
[Order article via Infotrieve]
-
Hoch, W.,
Campanelli, J. T.,
Harrison, S.,
and Scheller, R. H.
(1994)
EMBO J.
13,
2814-2821[Medline]
[Order article via Infotrieve]
-
Rupp, F.,
Payan, D. G.,
Magill-Solc, C.,
Cowan, D. M.,
and Scheller, R. H.
(1991)
Neuron
6,
811-823[CrossRef][Medline]
[Order article via Infotrieve]
-
Hopf, C.,
and Hoch, W.
(1996)
J. Biol. Chem.
271,
5231-5236[Abstract/Free Full Text]
-
Hopf, C.,
and Hoch, W.
(1997)
Eur. J. Neurosci.
9,
1170-1177[CrossRef][Medline]
[Order article via Infotrieve]
-
Hirano, Y.,
and Kidokoro, Y.
(1989)
J. Neurosci.
9,
1555-1561[Abstract]
-
Wallace, B. G.
(1990)
J. Neurosci.
10,
3576-3582[Abstract]
-
Godfrey, E. W.
(1991)
Exp. Cell Res.
195,
99-109[CrossRef][Medline]
[Order article via Infotrieve]
-
Hoch, W.,
Ferns, M.,
Campanelli, J. T.,
Hall, Z. W.,
and Scheller, R. H.
(1993)
Neuron
11,
479-490[CrossRef][Medline]
[Order article via Infotrieve]
-
Ferns, M. J.,
Campanelli, J. T.,
Hoch, W.,
Scheller, R. H.,
and Hall, Z.
(1993)
Neuron
11,
491-502[CrossRef][Medline]
[Order article via Infotrieve]
-
Denzer, A. J.,
Gesemann, M.,
Schumacher, B.,
and Ruegg, M. A.
(1995)
J. Cell Biol.
131,
1547-1560[Abstract/Free Full Text]
-
Tsen, G.,
Napier, A.,
Halfter, W.,
and Cole, G. J.
(1995)
J. Biol. Chem.
270,
15934-15937[Abstract/Free Full Text]
-
Denzer, A. J.,
Brandenberger, R.,
Gesemann, M.,
Chiquet, M.,
and Ruegg, M. A.
(1997)
J. Cell Biol.
137,
671-683[Abstract/Free Full Text]
-
Godfrey, E. W.,
Dietz, M. E.,
Morstad, A. L.,
Wallskog, P. A.,
and Yorde, D. E.
(1988)
J. Cell Biol.
106,
1263-1272[Abstract/Free Full Text]
-
Groffen, A. J. A.,
Ruegg, M. A.,
Dijkman, H. B. P. M.,
van der Velden, T. J.,
Buskens, C. A.,
van den Born, J.,
Assmann, K. J. M.,
Monnens, L. A. H.,
Veerkamp, J. H.,
and van den Heuvel, L. P. W. J.
(1998)
J. Histochem. Cytochem.
46,
19-27[Abstract/Free Full Text]
-
van den Born, J.,
van den Heuvel, L. P. W. J.,
Bakker, M. A. H.,
Veerkamp, J. H.,
Assmann, K. J. M.,
and Berden, J. H. M.
(1992)
Kidney Int.
41,
115-123[Medline]
[Order article via Infotrieve]
-
van den Heuvel, L. P. W. J.,
van den Born, J.,
van de Velden, T. J. A. M.,
Veerkamp, J. H.,
Monnens, L. A. H.,
Schroder, C. H.,
and Berden, J. H. M.
(1989)
Biochem. J.
264,
457-465[Medline]
[Order article via Infotrieve]
-
van den Born, J.,
van den Heuvel, L. P. W. J.,
Bakker, M. A. H.,
Veerkamp, J. H.,
Assmann, K. J. M.,
and Berden, J. H. M.
(1994)
J. Histochem. Cytochem.
42,
89-102[Abstract]
-
Raats, C. J. I.,
Bakker, M. A. H.,
van den Born, J.,
and Berden, J. H. M.
(1997)
J. Biol. Chem.
272,
26734-26741[Abstract/Free Full Text]
-
Greenwood, F. C.,
Hunter, W. M.,
and Glover, J. S.
(1963)
Biochem. J.
89,
114-123[Medline]
[Order article via Infotrieve]
-
van den Born, J.,
Gunnarsson, K.,
Bakker, M. A. H.,
Kjellen, L.,
Kusche-Gullberg, M.,
Maccarana, M.,
Berden, J. H. M.,
and Lindahl, U.
(1995)
J. Biol. Chem.
270,
31303-31309[Abstract/Free Full Text]
-
Campanelli, J. T.,
Roberds, S. L.,
Campbell, K. P.,
and Scheller, R. H.
(1994)
Cell
77,
663-674[CrossRef][Medline]
[Order article via Infotrieve]
-
van den Born, J.,
van den Heuvel, L. P. W. J.,
Bakker, M. A. H.,
Veerkamp, J. H.,
Assmann, K. J. M.,
Weening, J. J.,
and Berden, J. H. M.
(1993)
Kidney Int.
43,
454-463[Medline]
[Order article via Infotrieve]
-
Shimomura, H.,
and Spiro, R. G.
(1987)
Diabetes
36,
374-381[Abstract]
-
Nitkin, R. M.,
Smith, M. A.,
Magill, C.,
Fallon, J. R.,
Yao, Y.-M. M.,
Wallace, B. G.,
and McMahan, U. J.
(1987)
J. Cell Biol.
105,
2471-2478[Abstract/Free Full Text]
-
Ruegg, M. A.,
and Bixby, J. L.
(1998)
Trends Neurosci.
21,
22-27[CrossRef][Medline]
[Order article via Infotrieve]
-
Farquhar, M. G.,
Lemkin, M. C.,
and Stow, J. L.
(1985)
in
Nephrology (Robinson, R. R., ed), pp. 580-590, Springer-Verlag, New York
-
Kanwar, Y. S.,
Liu, Z. Z.,
Kashihara, N.,
and Wallner, E. I.
(1991)
Semin. Nephrol.
11,
390-413[Medline]
[Order article via Infotrieve]
-
O'Toole, J. J.,
Deyst, K. A.,
Bowe, M. A.,
Nastuk, M. A.,
McKenchnie, B. A.,
and Fallon, J. R.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
7369-7374[Abstract/Free Full Text]
-
Gesemann, M.,
Cavalli, V.,
Denzer, A. J.,
Brancaccio, A.,
and Schumacher, B.
(1996)
Neuron
16,
755-767[CrossRef][Medline]
[Order article via Infotrieve]
-
Glass, D. J.,
Bowen, D. C.,
Stitt, T. N.,
Radziejewski, C.,
Bruno, J.,
Ryan, T. E.,
Gies, D. R.,
Shah, S.,
Mattsson, K.,
Burden, S. J.,
DiStefano, P. S.,
Valenzuela, D. M.,
DeChiara, T. M.,
and Yancopoulos, G. D.
(1996)
Cell
85,
513-523[CrossRef][Medline]
[Order article via Infotrieve]
-
DeChiara, T. M.,
Bowen, D. C.,
Valenzuela, D. M.,
Simmons, M. V.,
Pouenymirou, W. T.,
Thomas, S.,
Kinetz, E.,
Compton, D. L.,
Rojas, E.,
Park, J. S.,
Smith, C.,
DiStefano, P. S.,
Glass, D. J.,
Burden, S. J.,
and Yancopoulos, G. D.
(1996)
Cell
85,
501-512[CrossRef][Medline]
[Order article via Infotrieve]
-
Valenzuela, D. M.,
Stitt, T. N.,
DiStefano, P. S.,
Rojas, E.,
Mattsson, K.,
Compton, D. L.,
Nunez, L.,
Park, J. S.,
Stark, J. L.,
Gies, D. R.,
Thomas, S.,
Le Beau, M. M.,
Fernald, A. A.,
Copeland, N. G.,
Jenkins, N. A.,
Burden, S. J.,
Glass, D. J.,
and Yancopoulos, G. D.
(1995)
Neuron
15,
573-584[CrossRef][Medline]
[Order article via Infotrieve]
-
Durbeej, M.,
Larsson, E.,
Ibraghimov-Beskrovnaya, O.,
Roberds, S. L.,
Campbell, K. P.,
and Ekblom, P.
(1995)
J. Cell Biol.
130,
79-91[Abstract/Free Full Text]
-
Gesemann, M.,
Brancaccio, A.,
Schumacher, B.,
and Ruegg, M. A.
(1998)
J. Biol. Chem.
273,
600-605[Abstract/Free Full Text]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. J.M. Wijnhoven, J. F.M. Lensen, R. G.P. Wismans, D. J. Lefeber, A. L.W.M.M. Rops, J. van der Vlag, J. H.M. Berden, L. P.W.J. van den Heuvel, and T. H. van Kuppevelt
Removal of Heparan Sulfate from the Glomerular Basement Membrane Blocks Protein Passage
J. Am. Soc. Nephrol.,
December 1, 2007;
18(12):
3119 - 3127.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Harvey, G. Jarad, J. Cunningham, A. L. Rops, J. van der Vlag, J. H. Berden, M. J. Moeller, L. B. Holzman, R. W. Burgess, and J. H. Miner
Disruption of Glomerular Basement Membrane Charge through Podocyte-Specific Mutation of Agrin Does Not Alter Glomerular Permselectivity
Am. J. Pathol.,
July 1, 2007;
171(1):
139 - 152.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W.A.M. Celie, N. W.P. Rutjes, E. D. Keuning, R. Soininen, R. Heljasvaara, T. Pihlajaniemi, A. M. Drager, S. Zweegman, F. L. Kessler, R. H.J. Beelen, et al.
Subendothelial Heparan Sulfate Proteoglycans Become Major L-Selectin and Monocyte Chemoattractant Protein-1 Ligands upon Renal Ischemia/Reperfusion
Am. J. Pathol.,
June 1, 2007;
170(6):
1865 - 1878.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J.M. Wijnhoven, J. F.M. Lensen, R. G.P. Wismans, M. Lamrani, L. A.H. Monnens, R. A. Wevers, A. L.W.M.M. Rops, J. van der Vlag, J. H.M. Berden, L. P.W.J. van den Heuvel, et al.
In Vivo Degradation of Heparan Sulfates in the Glomerular Basement Membrane Does Not Result in Proteinuria
J. Am. Soc. Nephrol.,
March 1, 2007;
18(3):
823 - 832.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. van den Born, B. Pisa, M. A. H. Bakker, J. W. A. M. Celie, C. Straatman, S. Thomas, G. C. Viberti, L. Kjellen, and J. H. M. Berden
No Change in Glomerular Heparan Sulfate Structure in Early Human and Experimental Diabetic Nephropathy
J. Biol. Chem.,
October 6, 2006;
281(40):
29606 - 29613.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kramer, M. van den Hoven, A. Rops, T. Wijnhoven, L. van den Heuvel, J. Lensen, T. van Kuppevelt, H. van Goor, J. van der Vlag, G. Navis, et al.
Induction of Glomerular Heparanase Expression in Rats with Adriamycin Nephropathy Is Regulated by Reactive Oxygen Species and the Renin-Angiotensin System
J. Am. Soc. Nephrol.,
September 1, 2006;
17(9):
2513 - 2520.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. P.J. Vogtlander, H. Dijkman, M. A.H. Bakker, K. P. Campbell, J. van der Vlag, and J. H.M. Berden
Localization of {alpha}-Dystroglycan on the Podocyte: from Top to Toe
J. Histochem. Cytochem.,
November 1, 2005;
53(11):
1345 - 1353.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Levidiotis, C. Freeman, M. Punler, P. Martinello, B. Creese, V. Ferro, J. van der Vlag, J. H.M. Berden, C. R. Parish, and D. A. Power
A Synthetic Heparanase Inhibitor Reduces Proteinuria in Passive Heymann Nephritis
J. Am. Soc. Nephrol.,
November 1, 2004;
15(11):
2882 - 2892.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Levidiotis, C. Freeman, C. Tikellis, M. E. Cooper, and D. A. Power
Heparanase Is Involved in the Pathogenesis of Proteinuria as a Result of Glomerulonephritis
J. Am. Soc. Nephrol.,
January 1, 2004;
15(1):
68 - 78.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Bengtsson, M. Morgelin, T. Sasaki, R. Timpl, D. Heinegard, and A. Aspberg
The Leucine-rich Repeat Protein PRELP Binds Perlecan and Collagens and May Function as a Basement Membrane Anchor
J. Biol. Chem.,
April 19, 2002;
277(17):
15061 - 15068.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Bezakova and T. Lomo
Muscle Activity and Muscle Agrin Regulate the Organization of Cytoskeletal Proteins and Attached Acetylcholine Receptor (AChR) Aggregates in Skeletal Muscle Fibers
J. Cell Biol.,
June 25, 2001;
153(7):
1453 - 1464.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C. Erickson and J. R. Couchman
Still More Complexity in Mammalian Basement Membranes
J. Histochem. Cytochem.,
October 1, 2000;
48(10):
1291 - 1306.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
C. J. I. Raats, J. van den Born, M. A. H. Bakker, B. Oppers-Walgreen, B. J. M. Pisa, H. B. P. M. Dijkman, K. J. M. Assmann, and J. H. M. Berden
Expression of Agrin, Dystroglycan, and Utrophin in Normal Renal Tissue and in Experimental Glomerulopathies
Am. J. Pathol.,
May 1, 2000;
156(5):
1749 - 1765.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. M. REGELE, E. FILLIPOVIC, B. LANGER, H. POCZEWKI, I. KRAXBERGER, R. E. BITTNER, and D. KERJASCHKI
Glomerular Expression of Dystroglycans Is Reduced in Minimal Change Nephrosis But Not in Focal Segmental Glomerulosclerosis
J. Am. Soc. Nephrol.,
March 1, 2000;
11(3):
403 - 412.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. GAMBARO and F. J. VAN DER WOUDE
Glycosaminoglycans: Use in Treatment of DiabeticNephropathy
J. Am. Soc. Nephrol.,
February 1, 2000;
11(2):
359 - 368.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. I. RAATS, M. E. LUCA, M. A. H. BAKKER, A. VAN DER WAL, P. HEERINGA, H. VAN GOOR, J. VAN DEN BORN, E. DE HEER, and J. H. M. BERDEN
Reduction in Glomerular Heparan Sulfate Correlates with Complement Deposition and Albuminuria in Active Heymann Nephritis
J. Am. Soc. Nephrol.,
August 1, 1999;
10(8):
1689 - 1699.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. M. Kachinsky, S. C. Froehner, and S. L. Milgram
A PDZ-containing Scaffold Related to the Dystrophin Complex at the Basolateral Membrane of Epithelial Cells
J. Cell Biol.,
April 19, 1999;
145(2):
391 - 402.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|